Bruker (NASDAQ:BRKR) Shares Cross Above 50-Day Moving Average – Time to Sell?

Bruker Corporation (NASDAQ:BRKR)’s share price passed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $58.79 and traded as high as $61.00. Bruker shares last traded at $60.74, with a volume of 2,384,762 shares changing hands.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on BRKR shares. Stifel Nicolaus set a $50.00 price objective on shares of Bruker in a research report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research report on Monday, August 31st. Zacks Research lowered shares of Bruker from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. JPMorgan Chase & Co. restated a “neutral” rating and issued a $60.00 price target on shares of Bruker in a report on Wednesday, October 14th. Finally, Leerink Partners upped their price objective on Bruker from $60.00 to $80.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Bruker currently has an average rating of “Moderate Buy” and an average target price of $59.43.

Bruker Stock Up 4.3%

The firm has a fifty day moving average price of $58.79 and a 200 day moving average price of $50.25.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The firm had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. Bruker’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Monday, September 21st were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date was Monday, September 21st.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total value of $105,740.00. Following the sale, the vice president owned 134,806 shares in the company, valued at $7,127,193.22. This represents a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 27.20% of the company’s stock.

Institutional Investors Weigh In On Bruker

Several hedge funds have recently added to or reduced their stakes in the business. Global Retirement Partners LLC bought a new position in shares of Bruker in the second quarter valued at about $38,000. Root Financial Partners LLC acquired a new position in Bruker in the 3rd quarter valued at about $57,000. Essential Partners LLC acquired a new position in Bruker in the 1st quarter valued at about $36,000. FNY Investment Advisers LLC bought a new position in Bruker in the 2nd quarter valued at about $60,000. Finally, IFP Advisors Inc boosted its holdings in shares of Bruker by 88.6% during the second quarter. IFP Advisors Inc now owns 1,060 shares of the medical research company’s stock worth $64,000 after acquiring an additional 498 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.